Emergent BioSolutions | EBS - PE Price to Earnings


Emergent BioSolutions reported 14.4 in PE Price to Earnings for its fiscal quarter ending in September of 2022.





Pe Change Date
Acadia Pharmaceuticals 11.61 2.09 Dec/2025
Akebia Therapeutics 26.5 0.19 Sep/2023
ALKERMES 19.54 4.64 Dec/2025
Alnylam Pharmaceuticals 170.7 367.33 Dec/2025
Amarin 91.05 88.3 Jun/2023
ANI Pharmaceuticals 37.99 60.68 Dec/2025
BioMarin Pharmaceutical 19.24 0.21 Dec/2025
Emergent BioSolutions 14.4 2.25 Sep/2022
Exelixis 602.31 586.25 Dec/2025
Glaxosmithkline 11.93 6.46 Sep/2025
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ironwood Pharmaceuticals 204.24 88.19 Dec/2024
Lexicon Pharmaceuticals 12.44 4.73 Jun/2021
Lonza 67.52 12.2 Jun/2024
Merck 13.92 5.08 Dec/2025
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 835.47 802.2 Dec/2025
Pacira 52.68 23.44 Dec/2025
Pfizer 14.48 5.18 Dec/2025
PTC Therapeutics 9.98 3.25 Dec/2025
Sanofi 11.99 1.58 Dec/2025
Sarepta Therapeutics 27.27 0 Sep/2025
United Therapeutics 17.32 1.62 Dec/2025
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Xoma 52.12 3.09 Sep/2022